• About Nektar
  • Our Leadership
  • Corporate Giving
  • Locations
  • Contacts
• Pipeline
  • Pipeline Overview
  • Nektar Proprietary Products
  • Nektar Partnered Products
  • Drug Development Platforms
• Partners
  • Nektar Partners
• Investor Relations
  • Press Releases
  • Stock Information
  • Financial Events Calendar
  • Analyst Coverage
  • Annual and Financial Reports
  • Corporate Governance
  • Investor Contacts
  • FAQ
  • Investor Advisory
• Media Room
  • Lead Product Backgrounder
  • Press Releases
  • Press Kit
  • Media Contacts
• Information Center
  • Scientific & Partnering Events
  • Multimedia
  • Library
  • Email Alerts
• Careers
  • Life at Nektar
  • Career Opportunities
  • Recruitment Calendar
  • Summer Internships
  • Benefits
  • Recruiting Information
  • Nektar Employee Foundation

• Pipeline Overview
• Nektar Proprietary Products
• Nektar Partnered Products
  • Approved or Filed Products
  • Pipeline Products
    • Inhaled Tobramycin
    • Inhaled Dronabinol
    • CDP 791®
    • NKTR-061
      (amikacin inhale)
• Drug Development Platforms

Our partnered product development pipeline contains products with potentially enormous therapeutic value in their respective disease categories. Partnering with top tier pharmaceutical companies, we provide our expertise in research and product development including preclinical, clinical, and regulatory support. These resources, combined with increased access to our proprietary assets, provide our partners with greater potential for success and shortened product development times.

Phase 3

• Inhaled Tobramycin (Novartis)
• Hematide (Affymax)
• SprayGel Adhesion Barrier System (Confluent)

Phase 2

• NKTR-061 (amikacin inhale)
• Ciprofloxacin (Bayer)
• CDP 791 (UCB Pharma)
• Dronabinol (Solvay Pharmaceuticals)
• Inhaled DHE (MAP Pharmaceuticals)

Phase 1

• Hematide (Affymax)